learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Search
forLearn
5 / 801 resultslearn thiamin
learn nicotinamide
learn microbiota modulator
learn medium chain triglycerides
Research
5 / 1000+ results
research Design and synthesis of novel Azasteroids and Pseudoazulenyl nitrones
The research created new azasteroids and pseudoazulenyl nitrones, which could be useful in medicine.
research Investigation on antimicrobial, antioxidant, and anti-cancerous activity of Agaricus bisporus derived β-Glucan against cervical cancer cell line
Agaricus bisporus derived β-Glucan could be an effective cervical cancer treatment with antimicrobial and antioxidant properties.
research Investigations on Kaempferol, Quercetin and Other Flavonoids in Aquatic Plants of Iraqi Marshlands-I
Flavonoids in Iraqi marshland plants have potential health benefits like antioxidant and anti-inflammatory effects.
research Advancing mitochondrial therapeutics: Synthesis and pharmacological evaluation of pyrazole-based inhibitors targeting the mitochondrial pyruvate carrier
New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
research Shaping Up Mitochondrion in Motion
Mitochondria change shape to meet energy needs during cell movement.
Community Join
5 / 1000+ resultscommunity Mystery compound found to be safe and effective at treating hair loss. Details in comments.
A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.
community PP405 Identity Research
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community GT20029. Kintor Pharma’s Product
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.